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Rationale: Basic science research suggests a causal role for endothe-
lial dysfunction in chronic obstructive pulmonary disease (COPD).
Clinical studies examining endothelial function are lacking, particu-
larly early in the disease. Flow-mediated dilation (FMD) is a physio-
logic measure of endothelial reactivity to endogenous nitric oxide.
Objectives:We hypothesized that lower FMDamong former smokers
would be associated with lower post-bronchodilator FEV1, higher
percentage of emphysema using computed tomography (CT) and
lower diffusing capacity.
Methods: We measured FMD, pulmonary function, and CT percent-
age of emphysema in a random sample of 107 cotinine-confirmed
former smokers in the ongoing EMCAP study. FMD was defined as
percentage change in the brachial artery diameter with reactive hy-
peremia.Generalizedadditivemodelswereused toadjust forpoten-
tial confounders and assess linearity.
Measurements and Main Results: Mean age of participants was 716 5
years, 46% were female, and pack-years averaged 48 6 26. Mean
FMD was 3.8 6 3.1%; mean post-bronchodilator FEV1, 2.3 6 0.8 L;
andmeanCTpercentage of emphysema, 266 10%. A 1 SDdecrease
in FMD was associated with a 132-ml (95% confidence interval, 16–
248ml; P5 0.03) decrement in post-bronchodilator FEV1 and a 2.6%
(95% confidence interval, 0.5–4.7%; P 5 0.02) increase in CT per-
centage of emphysema in fully adjusted models. These associations
were linear across the spectrum fromnormality to disease, indepen-
dent of smoking history, and also significant among participants
without COPD. Associations with diffusing capacity were consistent
butnonsignificant(P50.09).TheFMD–FEV1associationwasentirely
attributable to percentage of emphysema.
Conclusions: Impaired endothelial function, as measured by FMD,
was associatedwith lower FEV1 andhigherCTpercentage of emphy-
sema in former smokers early in COPD.
Keywords: pulmonary disease, chronic obstructive; bronchitis, chronic;
pulmonary emphysema; endothelial dysfunction
Recent research on the pathogenesis of chronic obstructive pul-
monary disease (COPD) suggests that perturbations in the vas-
culature and, specifically, endothelial health may occur early in
COPD (1). Decreased expression of vascular endothelial growth
factor (VEGF) causes endothelial apoptosis, epithelial apopto-
sis, and emphysema (2–4). The second messenger lipid ceramide
mediates VEGF blockade–induced apoptosis in COPD and cer-
amide instillation acutely triggers apoptosis in pulmonary endo-
thelial cells, causing emphysema in mice (5).
Apoptotic endothelial cells are present in the lungs of
smokers with COPD (6, 7), and there are significant morpho-
logic differences in the endothelium of smokers with mild, moder-
ate, and severe COPD compared with smokers without COPD
(8). Furthermore, nitric oxide (NO)-mediated, endothelium-
dependent relaxation provoked by adenosine diphosphate and
acetylcholine is attenuated in the excised pulmonary arteries of
patients with COPD compared with those of smoking and non-
smoking control subjects (9, 10). Published studies assessing
in vivo endothelial function in COPD are, however, lacking.
Measurement of endothelial function in the pulmonary vas-
cular bed in vivo requires invasive catheterization and is not
feasible in large numbers of relatively healthy patients. A nonin-
vasive measure of endothelial function is flow-mediated dilation
(FMD) of the brachial artery, which measures endothelium-
dependent, NO-mediated vasodilation (11, 12).
We tested the hypothesis that endothelial dysfunction, as as-
sessed by brachial artery FMD, would be associated with lower
post-bronchodilator FEV1, higher computed tomography (CT)
percentage of emphysema, and lower diffusing capacity for car-
bon monoxide (DLCO) among an unselected sample of former
smokers in an ongoing cohort study, the Emphysema and Cancer
ActionProject (EMCAP) study.Wechose this designover a case-
control study because we were interested in examining the con-
tinuum of changes in FMD in early and preclinical COPD, rather
than those thatmayoccur in late, severeCOPD.We restricted the
sample to former smokers because current cigarette smoking
causes acute reductions in FMD (13, 14).
Preliminary results from this study were previously presented
in abstract form (15).
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Basic science research suggests a potentially causal role for
endothelial dysfunction in chronic obstructive pulmonary
disease (COPD). Clinical studies examining endothelial
function are lacking, particularly early in the disease.
What This Study Adds to the Field
Endothelial dysfunction, measured by flow-mediated di-
lation, was associated with lower post-bronchodilator FEV1
and higher computed tomography percentage of emphy-
sema in former smokers across a spectrum from normal
lung function and anatomy to moderate to severe COPD
and emphysema.
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The EMCAP study recruited 557 participants at one site of a lung can-
cer CT screening research program (16) in 2001–2002. Inclusion criteria
were current and former smoking with 10 or more pack-years, age 60
years and older, willingness to undergo CT screening for lung cancer,
and no cancer history other than nonmelanoma skin cancer. Of 557
EMCAP participants, 313 (56%) denied current smoking at baseline and
follow-up and were hence eligible for the FMD study.
We invited a random sample of 196 of these former smokers to par-
ticipate in the FMD study, of whom 71 declined the FMD measure-
ment, 6 met FMD exclusion criteria of systolic blood pressure greater
than 180 mm Hg, Raynaud’s phenomenon, or prior total mastectomy,
and 119 completed the FMD measurement (61% of those invited). The
Columbia University Institutional Review Board approved all study
activities.
Measures
Participants underwent the following measures, each of which was
performed at approximately the same time in the morning and in the
following order.
FMD of the Brachial Artery
FMD was measured in 2005–2006 using a standardized protocol adapted
from a large multicenter study (17), consistent with published guide-
lines (18). Subjects fasted for 12 hours, avoided exercise for 6 hours,
and rested in the supine position for 15 minutes (18). Regular medi-
cations were not withheld. Brachial artery diameter was measured 6 cm
above the antecubital crease of the right arm using B-mode ultrasound
with a 15-MHz linear array transducer (SONOS 5500; Philips, Andover,
MA). A blood pressure cuff was inflated to at least 50 mm Hg above
systolic blood pressure to occlude arterial flow to the forearm for 5 minutes
(18), then brachial artery diameter was remeasured during reactive
hyperemia 1 minute after cuff deflation (19, 20). End-diastolic images
were digitized by a frame grabber (model LG3; Scion Corporation,
Frederick, MD).
A single reader blinded to clinical status measured all brachial
artery diameters off-line using analysis software for three consecutive
cardiac cycles at rest and 1 minute postdeflation for each participant.
FMD was expressed as percentage change from rest (100 3 [brachial
artery diameter during reactive hyperemia – diameter at rest]/diameter
at rest). Absolute intraobserver variability for FMD measurements was
1.3%.
Spirometry
Pre- and post-bronchodilator spirometry was performed according to
American Thoracic Society (ATS) guidelines (21) using the EasyOne
portable spirometer (ndd Medical Technologies, Chelmsford, MA),
which we previously validated against a dry seal, rolling-barrel spirom-
eter (22). Assessment of spirometry quality followed ATS/European
Respiratory Society (ERS) recommendations (23).
COPD and COPD severity were defined according to ATS/ERS
COPD criteria using post-bronchodilator measures (24).
CT Emphysema Index
All participants underwent low-dose, noncontrast, full-lung CT scan-
ning on a Siemens 16 multidetector scanner (120 kVp, 169 mAs, 6:1
pitch, 5-mm thickness, single breath-hold, contiguous slices from the
thoracic inlet to the adrenal glands). The CT percentage of emphysema
in the lungs was assessed as the proportion of lung volume below a
threshold attenuation of 2910 Hounsfield units (HU) compared with
the total volume of the lung. This measure is also commonly referred to
as the emphysema index or density mask (25). We modified the base
threshold to correct for interscan variations using the attenuation of
tracheal air. We first determined the average attenuation of a cylindri-
cal sample of air in the trachea taken above the bronchial branch point.
The attenuation of the sampled air was then compared with an average
attenuation of 2970 HU, with the difference used to correct the base-
line index attenuation of –910 HU.
DLCO
Single-breath DLCO was measured with a Sensormedics Autobox 220
Series instrument (Viasys Healthcare, Yorba Linda, CA) following
ATS/ERS guidelines (26). The participant exhaled to residual volume,
then was switched in to a gas mixture of 0.3% CO, 10% helium, 21%
oxygen, and balance nitrogen. The participant then inhaled rapidly to
total lung capacity, held his/her breath for 10 seconds, then exhaled to
residual volume. The average of all acceptable tests (minimum of two
tests) was reported. Breath-hold time was assessed by the method of
Jones and Meade (27).
Covariate Data
Information on age, sex, race/ethnicity, educational attainment, and phy-
sician diagnoses of cardiovascular diseases was recorded by interviewer-
administered questionnaire. Use of medications and supplements was
assessed by validated medication inventory (28). Blood pressure was
measured with mercury sphygmomanometers and cuffs of appropriate
size. Anthropometric measurements of height and weight were deter-
mined by the use of calibrated scales. Body mass index was calculated
as weight (kg) divided by height squared (m2).
Current smoking status was verified by urinary cotinine levels, which
were ascertained using enzyme-linked immunosorbent assay (Orasure
Technologies, Inc., Bethlehem, PA), according to the manufacturer’s
instructions. Current smoking was defined as urinary cotinine levels
above 500 ng/ml.
Statistical Analysis
Means and SDs were calculated. Age- and sex-adjusted associations of
FMD and potential confounders, such as statin use, were estimated in
linear regression models. The multivariate association of lung measures
and FMD was assessed in linear regression models that included age,
sex, race/ethnicity, height, pack-years of smoking, educational attain-
ment, asthma, body mass index, diabetes, hypertension, hypercholes-
terolemia, and use of statins, aspirin, b-blockers, omega-3 supplements,
and postmenopausal hormones (see Table 3). The statistical signifi-
cance of departures for linearity was tested in nested generalized ad-
ditive models with and without lowess (locally-weighted polynomial
regression) smoother functions. We decided a priori to adjust lung
measures for age, sex, race/ethnicity, and height rather than use
percent-predicted FEV1 and FVC due to the sizable proportion of par-
ticipants in this cohort for whom accurate prediction equations are
currently unavailable (U.S. Hispanics of non-Mexican origin and
Asian/Pacific Islanders). All P values were two-tailed with P , 0.05
considered statistically significant. Analyses were performed using SAS




FMD was measured in a random sample of 119 participants in
the EMCAP study who reported no current smoking. Of these,
eight with cotinine levels consistent with active smoking and four
with brachial artery images of insufficient quality for analysis were
excluded. The remaining 107 participants included in analyses were
similar to former smokers in the overall cohort with respect to
age, sex, race/ethnicity, smoking history, and prevalences of diag-
noses of hypertension, hypercholesterolemia, and COPD, but
had a lower prevalence of diagnosed diabetes (13 vs. 17%,P5 0.01).
Participants in the study sample were elderly, were evenly
divided between men and women, were 17% nonwhite, and had
moderately heavy smoking histories (Table 1). A majority had
hypercholesterolemia and 42% took a statin. Hypertension was
reported commonly, but mean blood pressures were within the
normal range and relatively few participants took a b-blocker or
angiotensin converting enzyme (ACE) inhibitor. A history of car-
diovascular disease was uncommon. Lung function in this sam-
ple of former smokers ranged from completely normal to severely
impaired. Of the total sample of 107 participants, a majority
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did not have COPD (defined as post-bronchodilator FEV1/FVC
ratio , 0.70), 12 (11%) had mild COPD, 21 (20%) had moder-
ate COPD, and 9 (9%) had severe or very severe COPD.
Table 1 also shows the characteristics of the former smokers
in the sample who did not have COPD. There were no signifi-
cant differences between the overall sample and those without
COPD, other than for pulmonary function and emphysema
measures.
FMD
The mean diameter of the brachial artery before cuff inflation in
the whole study sample was 3.86 0.7 mm. The mean increase in
brachial artery diameter during reactive hyperemia after cuff
deflation was 0.2 6 0.1 mm. The corresponding mean FMD, or
percentage of change in the brachial artery diameter, was 3.8 6
3.1%.
Table 2 shows mean differences in FMD and standard errors
by relevant covariates after adjustment for age and sex. There
were no large differences in FMD with respect to age and sex, al-
though Asian/Pacific Islanders had a larger response than other
race/ethnic groups. Cotinine levels among these former smokers
were not related to FMD, nor was obesity or height. FMD was
lower among patients with hypercholesterolemia, hypertension,
diabetes, and cardiovascular disease, although these differences
were large only for cerebrovascular disease and congestive heart
failure. Use of aspirin, statins, ACE inhibitors, b-blockers, and
omega-3 supplements were associated with lower FMD, and
postmenopausal hormone use was associated with higher FMD.
None of these associations approached even a nominal level of
statistical significance. Use of COPD medications, particularly
steroids and anticholinergics, were associated with relatively large
differences in FMD.
FMD and FEV1
The association of FMD with post-bronchodilator FEV1 is show
in Table 3. A 1SD decrease in FMD was associated with a 147-ml
(95% confidence interval [CI], 31–264 ml; P 5 0.01) decrement
in post-bronchodilator FEV1 after adjustment for age, sex, height,
and race/ethnicity (model 1). This association was essentially
unchanged after additional adjustment for pack-years of smoking
(model 2) and only slightly attenuated after additional adjust-
ment for educational attainment, body mass index, asthma, hy-
percholesterolemia, hypertension, and diabetes, and use of statins,
aspirin, b-blockers, omega-3 supplements, and postmenopausal
hormones (model 3).
Because the association of FMD and FEV1 in this study
spanned a range of post-bronchodilator lung function from nor-
mal to severe COPD, we examined the linearity of this associa-
tion to test if endothelial dysfunction measured by FMD occurred
predominantly late in the progression of COPD or if it was lin-
ear across the spectrum of lung dysfunction. Figure 1 shows that
the multivariate association of FMD and post-bronchodilator
FEV1 was approximately linear across this range of lung func-
tion. There was no graphical suggestion of a stronger relation-
ship in severe COPD manifest by a ‘‘hockey stick’’ shape rather
than a straight line. The multivariate relationship between FMD
and post-bronchodilator FEV1 in this flexible model was signif-
icant (P 5 0.02) and there was no evidence for a departure from
linearity (P 5 0.30). We confirmed these graphical analyses by
testing for effect modification of the FMD–FEV1 association by
COPD status in the full multivariate model and found no evi-
dence of an interaction (P 5 0.95).
Given the apparent linear relationship of FMD and post-
bronchodilator FEV1, we evaluated whether FMD was signifi-
cantly related to post-bronchodilator FEV1 among former smokers
who had not developed COPD. Among 63 participants without
TABLE 1. CHARACTERISTICS OF COTININE-CONFIRMED
FORMER SMOKERS WITH VALID FLOW-MEDIATED DILATION
MEASURES IN THE EMCAP STUDY AND THE SUBSET WHO







Age (mean 6 SD), yr 71 6 5 70 6 5
Female, % 46 46
Ethnicity, %
White 83 79
African American 6 6
Hispanic 8 10
Asian/Pacific Islander 3 5
Education, %
Graduate degree 28 24
Four-year college 32 41
High school/some college 35 32
No high school degree 6 3
Cotinine level (mean 6 SD), ng/ml 14 6 39 16 6 49
Pack-years, mean 6 SD 48 6 26 44 6 24
Height (mean 6 SD), cm 168 6 9 167 6 9
BMI (mean 6 SD), kg/m2 28 6 4 28 6 4




Coronary heart disease 3 3
Cerebrovascular disease 4 3
Peripheral vascular disease 6 3
Congestive heart failure 2 3
Sleep apnea 6 10
Cardiovascular medications, %
Aspirin 63 63
HMG-CoA reductase inhibitor (statin) 42 41
b-blocker 12 14
ACE inhibitor 12 16
Omega-3 supplement 35 33
Postmenopausal hormones† 22 16
Blood pressure (mean 6 SD), mm Hg
Systolic 128 6 15 128 6 16
Diastolic 73 6 9 73 6 9
Physician-diagnosed asthma before age 45 yr, % 9 8
MRC-defined chronic bronchitis, % 19 16
COPD medications, %
Short-acting b-agonists 13 5
Long-acting b-agonists 14 6
Short-acting anticholinergic 6 2
Long-acting anticholinergic 7 0
Theophylline 0 0
Inhaled corticosteroids 8 5
Systemic corticosteroids 1 0
Prebronchodilator FVC (mean 6 SD), L 3.17 6 0.91 3.16 6 0.77
Prebronchodilator FEV1 (mean 6 SD), L 2.20 6 0.71 2.38 6 0.62
Prebronchodilator FEV1/FVC ratio,
mean 6 SD
0.69 6 0.11 0.72 6 0.08
Post-bronchodilator FVC (mean 6 SD), L 3.25 6 0.95 3.27 6 0.77
Post-bronchodilator FEV1 (mean 6 SD), L 2.31 6 0.76 2.52 6 0.59
Post-bronchodilator FEV1/FVC ratio,
mean 6 SD
0.71 6 0.11 0.77 6 0.04





Severe or very severe 9
DLCO (mean 6 SD), ml/min/mm Hg 17.8 6 5.1 18.4 6 4.1
DLCO/VA, mean 6 SD 3.9 6 0.7 4.0 6 0.6
CT emphysema index (mean 6 SD), % 26.1 6 10.5 24.0 6 8.6
Definition of abbreviations: ACE 5 angiotensin converting enzyme; BMI 5 body
mass index; COPD 5 chronic obstructive pulmonary disease; CT 5 computed
tomography; DLCO 5 carbon monoxide diffusing capacity; EMCAP 5 Emphy-
sema and Cancer Action Project; HMG-CoA 5 3-hydroxy-3-methyl-glutaryl-
coenzyme A; MRC 5 Medical Research Council; VA 5 alveolar volume.
* Defined as post-bronchodilator FEV1/FVC ratio , 0.70.
† Among women only.
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COPD, the magnitude of the association of FMD and post-
bronchodilator FEV1 was the same as in the overall sample;
standard errors were smaller such that statistical significance
was retained in all models for FEV1 (Table 3). Nonlinear ana-
lyses yielded similar results as those for the overall sample.
In contrast, the association of FMD with post-bronchodilator
FVC was of borderline statistical significance in the whole sam-
ple (multivariate difference in FVC, 131 ml [95%CI, 2–259 ml] per
1 SD change in FMD; P 5 0.050) and was not statistically sig-
nificant in those without COPD (112 ml [95% CI,222 to 245 ml];
P 5 0.11). FMD was positively but not significantly associated
with the post-bronchodilator FEV1/FVC ratio in both the whole
sample (multivariate difference in FEV1/FVC ratio, 1.3% [95%CI,
20.9 to 3.5%] per 1 SD change in FMD; P 5 0.25) and in those
without COPD (0.6% [95% CI, 20.6 to 1.9%]; P 5 0.11).
Analyses of FMD and prebronchodilator spirometry meas-
ures yielded similar results to post-bronchodilator results. For
example, a 1-SD decrease in FMD was associated with a 153-ml
(95% CI, 48–257 ml; P 5 0.005) decrement in prebronchodila-
tor FEV1 in the full multivariate model among all participants.
There was no association of FMD with bronchodilator response
(20.75% [95% CI, 22.3 to 0.76%]; P 5 0.33).
FMD and CT Percentage of Emphysema
Findings for CT percentage of emphysema (Table 3) were sim-
ilar to those for FEV1. A 1-SD decrease in FMD was associated
with a 2.5% (95% CI, 0.1–4.8%; P 5 0.04) absolute increase in
CT percentage of emphysema after adjustment for age, sex,
height, and race/ethnicity. The association was unchanged after
additional adjustment for pack-years of smoking and in the full
multivariate model.
Figure 2 shows that the multivariate association of FMD and
CT percentage of emphysema was approximately linear across
the range of emphysema; there was no suggestion of a stronger
relationship in severe COPD. The multivariate relationship be-
tween FMD and CT percentage of emphysema in this flexible
model was highly significant (P 5 0.005), and there was no evi-
dence for a departure from linearity (P 5 0.24). Furthermore,
there was no effect modification of the FMD–emphysema asso-
ciation by COPD (P 5 0.96).
In analyses restricted to participants without COPD, the
magnitude of the association between FMD and CT percentage
of emphysema was similar to the overall sample in models 1 and
2 (Table 3), and the relationship was statistically significant in
the full multivariate model (model 3).
FMD and DLCO
Associations of FMD for DLCO were consistent with those for
FEV1 and CT percentage of emphysema but did not attain sta-
tistical significance in the whole sample (Table 3, P 5 0.09).
Unlike for FEV1 and percentage of emphysema, three values
for DLCO were highly influential outliers in the multivariate
models (Cook’s distance . 6%). Exclusion of these three values
improved the model fit appreciably and yielded a multivariate
difference in DLCO of 0.89 ml/minute/mm Hg (95% CI, 0.02–
1.77; P 5 0.049) per 1 SD change in FMD. Restriction to partic-
ipants without COPD yielded consistent, nonsignificant results
(Table 3).
Additional Analyses
We explored the joint association of FMDwith post-bronchodilator
FEV1 and CT percentage of emphysema in post hoc analyses.
The association between FMD and CT percentage of emphy-
sema was independent of and unchanged after adjustment for
post-bronchodilator FEV1 (P 5 0.015). In contrast, the associ-
ation between FMD and post-bronchodilator FEV1 was entirely
explained by adjustment for CT percentage of emphysema (P5
0.99).
When the main analyses were repeated with the inclusion of
the eight current smokers, results were very similar. The full
multivariate models yielded a significance of P5 0.027 for FEV1
andP5 0.013 forCTpercentage emphysema.Adjustment for use
of COPD medications did not change associations appreciably
(P 5 0.039 and P 5 0.019 for FEV1 and CT percentage of em-
physema, respectively), nor did exclusion of the small number of
participants with sleep apnea (P 5 0.020 and P 5 0.017, re-
spectively), or cardiovascular disease and congestive heart failure
(P 5 0.021 and P 5 0.014, respectively).
TABLE 2. AGE- AND SEX-ADJUSTED MEAN DIFFERENCES IN
FLOW-MEDIATED DILATION OF THE BRACHIAL ARTERY
(PERCENTAGE OF CHANGE IN ARTERY DIAMETER DURING














Age (per 10 yr) 20.390 0.636 20.436 0.789
Gender, female 20.074 0.613 20.294 0.786
Ethnicity
White Reference Reference
African American 0.371 1.400 0.473 1.717
Hispanic 20.187 1.114 20.0979 1.358
Asian/Pacific Islander 1.455 1.911 1.102 1.959
Education
Graduate degree Reference Reference
Four-year college 0.029 0.812 21.023 1.011
High school/some college 20.097 0.790 21.139 1.058
No high school degree 20.482 1.433 23.081 2.324
Cotinine level, ng/ml 20.006 0.008 20.007 0.008
Pack-years (per 10 pack-years) 0.001 0.012 0.016 0.016
Height (per 10 cm) 20.18 0.052 20.043 0.063
BMI (per 1 kg/m2) 0.012 0.072 20.080 0.093
Physician diagnosis of the following
Hypercholesterolemia 20.838 0.672 20.626 0.874
Hypertension 20.555 0.616 20.658 0.779
Diabetes 20.384 0.938 20.675 1.066
Coronary heart disease 20.905 1.896 0.791 2.290
Cerebrovascular disease 21.429 1.642 22.279 2.2278
Peripheral vascular disease 20.276 1.335 2.560 2.240
Congestive heart failure 22.067 2.329 22.808 2.340
Sleep apnea 0.174 1.329 0.387 1.357
Medications
Aspirin 20.447 0.637 1.009 0.807
HMG-CoA reductase
inhibitor (statin)
20.250 0.650 20.445 0.836
b-blocker 20.640 0.948 20.324 1.138
ACE inhibitor 20.441 0.950 20.145 1.125
Omega-3 supplement 20.962 0.646 21.056 0.866
Postmenopausal hormones 0.782 1.171 0.398 1.934
Blood pressure (per 10 mm Hg)
Systolic 20.032 0.021 20.0343 0.025
Diastolic 0.048 0.034 0.0242 0.043
Physician-diagnosed
asthma before age 45 yr
20.783 1.074 20.102 1.454
MRC-defined chronic bronchitis 20.278 0.793 0.267 1.082
COPD medications
Short-acting b-agonists 21.050 0.903 2.389 1.860
Long-acting b-agonists 21.134 0.875 21.179 1.643
Short-acting anticholinergic 22.825 1.315
Long-acting anticholinergic 21.451 1.240
Inhaled corticosteroids 22.386 1.083 22.546 1.811
Systemic corticosteroids 23.247 3.190
See Table 1 for definition of abbreviations.
* Defined as post-bronchodilator FEV1/FVC ratio , 0.70.
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DISCUSSION
We observed a strong, linear association of endothelial function
as measured by FMD with both post-bronchodilator FEV1 and
CT percentage of emphysema in former smokers across the
spectrum of disease from normal lung function to moderately
severe COPD. These associations were independent of smoking
and other major causes of endothelial dysfunction and COPD,
and were present among participants without COPD. The re-
lationship between FMD and post-bronchodilator FEV1 was
explained entirely by percentage of emphysema, which suggests
that changes in percentage of emphysema may mediate the re-
lationship of FMD and FEV1. These results provide in vivo
evidence in humans to support basic research studies (1–5) that
suggest that endothelial dysfunction might be involved in the
pathogenesis of emphysema and, secondarily, COPD.
To our knowledge, published studies on FMD in patients with
COPD are lacking. However, two case-control studies of more
severe COPDwere recently presented in abstract form. Eickhoff
and colleagues found appreciably lower FMD in patients with
moderate to severe COPD compared with smoking control sub-
jects and a strong correlation of FMD and FEV1 in patients with
COPD (29). Teramoto and coworkers found similar relationships
in severeCOPD (30). Both of these studies, however, used a case-
control design and hence were unable to assess associations early
in the disease or separately for FEV1 and CT percentage of
emphysema.
Other studies have found abnormalities in systemic vascular
function in COPD. Sabit and colleagues recently reported greater
aortic pulse wave velocity among patients with COPD compared
with unmatched controls (31), and Zureik and colleagues previ-
ously demonstrated an inverse associationbetween carotid-femoral
TABLE 3. MULTIVARIATE MEAN DIFFERENCES IN FEV1, PERCENTAGE OF EMPHYSEMA, AND
DIFFUSING CAPACITY PER 1 SD CHANGE IN FLOW-MEDIATED DILATION OF THE BRACHIAL
ARTERY IN FORMER SMOKERS
Former Smokers
(n 5 107)
Former Smokers without COPD
(n 5 63)
Difference in Lung Measure per
1 SD Change in FMD
(95% CI) P Value
Difference in Lung Measure per
1 SD Change in FMD
(95% CI) P Value
Post-bronchodilator FEV1, ml
Model 1* 147 (31, 264) 0.015 148 (55, 241) 0.003
Model 2† 148 (34, 263) 0.013 151 (57, 245) 0.003
Model 3‡ 132 (16, 248) 0.029 107 (7, 207) 0.042
CT percentage of emphysema
Model 1* 22.5 (24.8, 20.1) 0.041 22.3 (25.3, 0.7) 0.144
Model 2† 22.5 (24.9, 20.1) 0.046 22.4 (25.3, 0.6) 0.128
Model 3‡ 22.6 (24.7, 20.5) 0.018 23.5 (26.1, 20.8) 0.017
DLCO, ml/min/mm Hg
Model 1* 0.708 (20.088, 1.505) 0.085 0.399 (20.304, 1.103) 0.271
Model 2† 0.712 (20.087, 1.511) 0.084 0.387 (20.330, 1.104) 0.295
Model 3‡ 0.708 (20.088, 1.504) 0.088 0.461 (20.319, 1.240) 0.254
Definition of abbreviations: CI 5 confidence interval; COPD 5 chronic obstructive pulmonary disease; CT 5 computed
tomography; FMD 5 flow-mediated dilation.
* Model 1 adjusted for age, sex, race/ethnicity, and height.
† Model 2 adjusted for age, sex, race/ethnicity, height, and pack-years.
‡ Model 3 adjusted for age, sex, race/ethnicity, height, pack-years, educational attainment, asthma, body mass index, diabe-
tes, hypertension, hypercholesterolemia, and use of statins, aspirin, b-blockers, omega-3 supplements, and postmenopausal
hormones.
Figure 1. Multivariate association of the post-
bronchodilator FEV1 and flow-mediated dilation
(FMD) of the brachial artery in former smokers.
Solid line 5 smoothed regression line adjusted for
covariates listed in Table 3, model 3; dashed lines 5
95% confidence intervals; vertical lines5 rug plot of
data points. The multivariate relationship between
FEV1 and FMD was statistically significant (P 5
0.02). The smoothed curve did not differ signifi-
cantly from a straight line (P 5 0.30), suggesting
a linear relationship between FEV1 and FMD.
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pulse wave velocity and FEV1 (32). These studies are generally
consistent with our findings but are not specific for endothelial
function because pulse wave velocity is a measure of arterial
stiffness. Abnormal vascular stiffness in COPD may result from
diffuse subclinical atherosclerosis or primary abnormalities in
elastin in both the lung parenchyma and in the adventitia of
large vessels such as the aorta. FMD, in contrast, is a marker of
endothelial function and measures NO-mediated, endothelium-
dependent relaxation. A limitation of the current study is
the lack of a measure of endothelium-independent vasodilation,
which was not made for reasons relating to participant burden
in this ongoing cohort study. Abnormal vascular stiffness, how-
ever, would not explain the results of a study that showed
markedly reduced endothelial progenitor cells in severe COPD
(33).
The hypothesis of a primary vascular insult in COPD is not
new. The pathologist A. A. Liebow postulated almost 50 years
ago that changes in the local vascular milieu modulate alveolar
destruction in COPD (34). More recent research has shown that
smoking causes acute endothelial dysfunction (13, 14). The mech-
anisms by which this occurs are not clear, but one potential causal
agent is acrolein (35), which triggers endothelial apoptosis of hu-
man pulmonary microvascular endothelial cells via suppression
of prostaglandin (PG) I2 gene expression (36). Endothelial
apoptosis may in turn lead to microvascular damage in the
lungs and subsequent emphysema.
An alternative explanation for our findings is that aspects of
COPD and emphysema may cause endothelial dysfunction, be-
cause the cross-sectional design of this study is not well suited to
determination of the direction of causality. Hypoxemia, infec-
tion, inflammation, system stress, and pulmonary hypertension
may all impair FMD, may be caused by severe COPD, and were
not measured directly in this study. They are generally likely,
however, to be mild or absent in smokers without COPD, in
whom associations between FMD and post-bronchodilator FEV1
and CT percentage of emphysema were present. At a minimum,
the linear associations of FMD with lung function and lung
density document endothelial dysfunction in mild and ‘‘pre’’-
COPD and emphysema.
Confounding by factors known to lower FMD and cause
COPD, such as cigarette smoking, might also have led to our
findings. Current smokers were excluded using cotinine levels.
Additional adjustment for cotinine levels as a measure of envi-
ronmental tobacco smoke did not alter results (data not shown).
Medications such as statins and postmenopausal hormones im-
prove endothelial function, but adjustment for these medica-
tions assessed via a validated medication inventory (28) did not
alter findings appreciably. Other potential confounders includ-
ing age, sex, race/ethnicity, socioeconomic status, and obesity
were adjusted for with flexible multivariate models. Nonethe-
less, FMD is affected by a large number of factors and behaviors
(18), so it remains possible that unmeasured confounding contrib-
uted to some of the observed associations.
We did not include clinical cardiovascular disease in the
multivariate models because endothelial dysfunction is a cause
of myocardial infarctions and stroke, not an effect of them, and
hence, clinical cardiovascular disease is not a causal confounder
of the observed associations. Secondary analyses in which pa-
tients with clinical cardiovascular disease were excluded showed
consistent, significant results. We found relatively strong asso-
ciations between FMD and medications for COPD in age- and
sex-adjusted analyses; however, it is unclear if COPD medica-
tions affect FMD or if they were just prescribed for patients
with moderate to severe COPD who had low FMD. FMD is not
impaired by elevations in plasma epinephrine in experimental
settings (37). Intravenous administration of acetylcholine and
cortisol antagonists do affect FMD (38); however, the doses of
inhaled anticholinergics that are absorbed and circulate to the
brachial artery are low. Additional adjustment of COPD
medications did not explain associations of FMD and lung
measures, and associations were present in patients without
COPD who were not administered these medications.
FMD of the brachial artery has been validated against in-
tracoronary endothelial reactivity (11, 12). We did not validate
it, however, against endothelial reactivity in the pulmonary cir-
culation. The systemic nature of endothelial function makes it
likely, although not certain, that changes in endothelial function
in the brachial and coronary circulations also occur in the pul-
monary circulation.
FMDwasmeasured in this study at 1minute after cuff deflation.
This approach has previously been related to cardiovascular out-
comes and risk (39, 40) but differs slightly frompeak FMD,which
can occur before or after 1 minute after cuff deflation. Both ap-
proaches are consistent with published FMD guidelines (18).
Figure 2. Multivariate association of the computed
tomography (CT) percentage of emphysema and
flow-mediated dilation (FMD) of the brachial artery
in former smokers. Solid line5 smoothed regression
line adjusted for covariates listed in Table 3, model
3; dashed lines 5 95% confidence intervals; vertical
lines 5 rug plot of data points. The multivariate re-
lationship between CT percentage of emphysema
and FMD was statistically significant (P 5 0.005).
The smoothed curve did not differ significantly from
a straight line (P 5 0.24), suggesting a linear rela-
tionship between CT percentage of emphysema
and FMD.
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An additional limitation of the study was its relatively small
size to assess associations for DLCO and FEV1/FVC ratio, which
are prone to more measurement error than, for example, FEV1
(23, 26). The association of FMD with DLCO was consistent with
the study’s overall hypotheses but was not statistically signifi-
cant in the main analysis. The single-breath assessment of DLCO
used in this study may have resulted in an underestimation of
the true FMD–DLCO association because single-breath VA un-
derestimates true TLC in emphysema (41) and single-breath
DLCO correlates poorly with gas exchange in COPD (42). Ex-
clusion of extreme outliers of DLCO, however, resulted in a sig-
nificant association with FMD.
In conclusion, we found that endothelial dysfunction mea-
sured by FMD was independently associated with FEV1 and CT
percentage of emphysema in former smokers. These associa-
tions were linear across a spectrum of disease from normal lung
function and anatomy to moderate to severe COPD and em-
physema. This novel finding of endothelial dysfunction early in
COPD and emphysema requires replication in larger and
longitudinal cohorts, but it is consistent with basic science
research hypothesizing a primary vascular role in the patho-
genesis of COPD.
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